BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20534798)

  • 1. Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).
    Messer SA; Jones RN; Moet GJ; Kirby JT; Castanheira M
    J Clin Microbiol; 2010 Aug; 48(8):2984-7. PubMed ID: 20534798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.
    Castanheira M; Woosley LN; Diekema DJ; Messer SA; Jones RN; Pfaller MA
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2655-9. PubMed ID: 20368396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).
    Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Jan; 69(1):45-50. PubMed ID: 21146713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
    Pfaller MA; Carvalhaes C; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).
    Pfaller MA; Messer SA; Jones RN; Castanheira M
    J Antibiot (Tokyo); 2015 Sep; 68(9):556-61. PubMed ID: 25899126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
    Pfaller MA; Castanheira M; Messer SA; Jones RN
    Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Int J Antimicrob Agents; 2017 Sep; 50(3):352-358. PubMed ID: 28689871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.
    Castanheira M; Messer SA; Jones RN; Farrell DJ; Pfaller MA
    Int J Antimicrob Agents; 2014 Oct; 44(4):320-6. PubMed ID: 25129315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.
    Espinel-Ingroff A; Arendrup M; Cantón E; Cordoba S; Dannaoui E; García-Rodríguez J; Gonzalez GM; Govender NP; Martin-Mazuelos E; Lackner M; Lass-Flörl C; Linares Sicilia MJ; Rodriguez-Iglesias MA; Pelaez T; Shields RK; Garcia-Effron G; Guinea J; Sanguinetti M; Turnidge J
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
    Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
    J Antimicrob Chemother; 2016 Oct; 71(10):2868-73. PubMed ID: 27287236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).
    Messer SA; Jones RN; Fritsche TR
    J Clin Microbiol; 2006 May; 44(5):1782-7. PubMed ID: 16672407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007).
    Messer SA; Moet GJ; Kirby JT; Jones RN
    J Clin Microbiol; 2009 Jun; 47(6):1942-6. PubMed ID: 19386851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
    Castanheira M; Deshpande LM; Davis AP; Rhomberg PR; Pfaller MA
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous Mutational Frequency and
    Shields RK; Kline EG; Healey KR; Kordalewska M; Perlin DS; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro activity of anidulafungin. Comparison with the activity of other echinocandins].
    Martín Mazuelos E; Rodríguez-Tudela JL
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():7-13. PubMed ID: 19572429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species.
    Fiori B; Posteraro B; Torelli R; Tumbarello M; Perlin DS; Fadda G; Sanguinetti M
    Antimicrob Agents Chemother; 2011 Jun; 55(6):3031-5. PubMed ID: 21422210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria.
    Pfaller MA; Diekema DJ; Jones RN; Castanheira M
    J Clin Microbiol; 2014 Sep; 52(9):3223-9. PubMed ID: 24951808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of Candida spp. isolates: Identification and echinocandin susceptibility in isolates obtained from blood cultures in 15 hospitals in Medellín, Colombia.
    Berrio I; Maldonado N; De Bedout C; Arango K; Cano LE; Valencia Y; Jiménez-Ortigosa C; Perlin DS; Gómez BL; Robledo C; Robledo J;
    J Glob Antimicrob Resist; 2018 Jun; 13():254-260. PubMed ID: 29183771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.